Evidence map›Paper›PMID 26028346›Full record

Trial reportOphthalmology2015

VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

Stephanie A Hagstrom, Gui-shuang Ying, Maureen G Maguire, Daniel F Martin, CATT Research Group, Jane Gibson, Andrew Lotery, Usha Chakravarthy, IVAN Study Investigators

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00593450 (Comparison of Age-related Macular Degeneration Treatments Trials), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00593450 phase3completednot on this map

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)

TypeinterventionalSponsorUniversity of PennsylvaniaRan2008 to 2015Enrolled1,208ConditionsAge Related Macular DegenerationArmsranibizumab, bevacizumab
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Risk factors and biomarkers of age-related macular degeneration.Progress in retinal and eye research · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Stephanie A HagstromCole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. Electronic address: hagstrs@ccf.org.
Gui-shuang YingDepartment of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
Maureen G MaguireDepartment of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
Daniel F MartinCole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.
CATT Research Group
Jane GibsonCentre for Biological Sciences, University of Southampton, Southampton, United Kingdom.
Andrew LoteryFaculty of Medicine, University of Southampton, Southampton, United Kingdom.
Usha ChakravarthyDepartment of Ophthalmology, Queen's University, Belfast, United Kingdom.
IVAN Study Investigators
Cleveland Clinic Lerner College of Medicine · USUniversity of Pennsylvania · USUniversity of Southampton · GBQueen's University Belfast · GB

Funding

Coordinating Center for the Comparison of AMD Treatments TrialsU10EY017823 · NEI · UNIVERSITY OF PENNSYLVANIA · PI MAGUIRE, MAUREEN G · 2006 to 2012
$19.2M
Photograph Reading Center for the Comparison of AMD Treatment TrialsU10EY017826 · NEI · UNIVERSITY OF PENNSYLVANIA · PI GRUNWALD, JUAN E · 2006 to 2013
$2.8M
Comparison of AMD Treatment Trials-OCT Reading CenterU10EY017825 · NEI · DUKE UNIVERSITY · PI JAFFE, GLENN · 2006 to 2013
$2.3M
Chair Grant for the Comparison of AMD Treatment TrialsU10EY017828 · NEI · EMORY UNIVERSITY · PI MARTIN, DANIEL F · 2006 to 2012
$1.9M
Secondary Data Analysis of the Data from Comparison of AMD Treatments TrialsR21EY023689 · NEI · UNIVERSITY OF PENNSYLVANIA · PI YING, GUI-SHUANG · 2013 to 2014
$436k
NEI NIH HHS R21 EY023689NEI NIH HHS R21EY023689NEI NIH HHS U10 EY017823NEI NIH HHS U10 EY017825NEI NIH HHS U10 EY017826NEI NIH HHS U10 EY017828
6 · The paper itself

Abstract

purposeA previously published study demonstrated a pharmacogenetic association between the minor alleles of 2 VEGFR2 single nucleotide polymorphisms (SNPs) and greater improvement in visual acuity (VA) to treatment with ranibizumab, an anti-vascular endothelial growth factor (VEGF) drug, in patients with neovascular age-related macular degeneration (AMD). We evaluated whether this association was replicated among patients who participated in the Comparison of AMD Treatments Trials (CATT) or the Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) trial.

designCohort studies within randomized clinical trials.

participantsEight hundred thirty-five patients participating in CATT and 512 patients participating in IVAN.

methodsEach patient was genotyped for the SNPs rs4576072 and rs6828477 in the VEGFR2 gene. MAIN OUTCOMES MEASURES: Mean change in VA from baseline to 1 year after initiation of treatment with ranibizumab or bevacizumab. Differences in VA response between the patient group homozygous for the minor allele of each SNP and the other genotype groups were evaluated with analysis of variance. Differences in VA response by the number of minor alleles present for either SNP or both combined were evaluated with tests of linear trend. Analyses were conducted separately for CATT and IVAN participants and with both the studies combined.

resultsNo statistically significant difference in mean change in VA was identified between genotypes of either SNP (P ≥ 0.05). Furthermore, a stepwise analysis failed to show a significant interaction for either SNP based on the number of minor alleles present. The lack of association was similar in both the CATT and IVAN cohorts and whether the analysis combined patients treated with either ranibizumab or bevacizumab or when restricted to patients treated with ranibizumab only.

conclusionsThe CATT and IVAN data do not support a pharmacogenetic association between the 2 VEGFR2 SNPs, rs4576072 and rs6828477, and change in VA in response to anti-VEGF therapy in patients with neovascular AMD.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedFemaleGene FrequencyGenotyping TechniquesHumansIntravitreal InjectionsMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideRanibizumabTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedKDR protein, humanRanibizumabVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, human

Identifiers

PMID26028346
PMCPMC4516643
OpenAlexW1650810542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.